Efficacy and Safety of Nanocurcumin in Patients with Heart Failure Reduced Ejection Fraction; A Randomized Placebo-Controlled Clinical Trial
Publish place: Health Education & Health Promotion، Vol: 11، Issue: 4
Publish Year: 1402
نوع سند: مقاله ژورنالی
زبان: English
View: 33
This Paper With 6 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_HEHP-11-4_012
تاریخ نمایه سازی: 7 اسفند 1402
Abstract:
Aims: Heart failure reduced ejection fraction (HFrEF) is defined as symptoms, such as shortness of breath and edema with an ejection fraction of less than ۴۰% in echocardiography. Regarding the pathogenesis, the role of inflammation is undeniable. Interleukin ۶ (IL-۶) is one of the pro-inflammatory cytokines that is important in cardiovascular disease and has a critical role in CAD. It is also related to complications caused by heart failure and mortality. Nanocurcumin is a polyphenol extracted from the rhizome of Curcuma longa (turmeric) with better bioavailability. Effects of nanocurcumin on the reduction of IL-۶ and NT-proBNP in hospitalized HFrEF patients with acute decompensation were investigated.
Materials & Methods: Sixty patients with HFrEF admitted with acute heart failure were divided into the intervention group with the administration of ۴۰ mg of nanocurcumin twice a day for seven days and the control group (placebo). The levels of electrolytes, creatinine, IL-۶, and NT-proBNP were measured at baseline and after one week.
Findings: There was no statistically significant difference in the reduction in IL-۶ and NT-proBNP levels in the intervention and control groups (p>۰.۰۵). Also, there was no significant difference in creatinine and estimated glomerular filtration rate in the two groups (p>۰.۰۵).
Conclusion: Nanocurcumin at a dose of ۴۰ mg twice a day for seven days in patients with acute decompensated heart failure did not reduce IL-۶ and NT-proBNP levels.
Keywords:
Authors
Y. Panahi
Pharmacotherapy Department, School of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran
M. Sadeghi Ghahroudi
Atherosclerosis Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
E. Hosseinjani
“Department of Cardiology, School of Medicine” and “Shahid Labbafinezhad Hospital”, Shahid Beheshti University of Medical Sciences, Tehran Iran
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :